tradingkey.logo
tradingkey.logo
Search

Bluejay Diagnostics Inc

BJDX
Add to Watchlist
1.670USD
-0.040-2.29%
Close 05/15, 16:00ETQuotes delayed by 15 min
1.73MMarket Cap
LossP/E TTM

Bluejay Diagnostics Inc

1.670
-0.040-2.29%

More Details of Bluejay Diagnostics Inc Company

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc Info

Ticker SymbolBJDX
Company nameBluejay Diagnostics Inc
IPO dateNov 10, 2021
CEODey (Neil)
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 10
Address360 Massachusetts Avenue, Suite 203
CityACTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01720
Phone19786310152
Websitehttps://bluejaydx.com/
Ticker SymbolBJDX
IPO dateNov 10, 2021
CEODey (Neil)

Company Executives of Bluejay Diagnostics Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
25.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
2.00
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
25.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
2.00
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--

Revenue Breakdown

FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lichti (Braeden William Sinclair)
2.37%
Intracoastal Capital, L.L.C.
1.72%
Armistice Capital LLC
1.57%
Northstrive Fund II LP
1.06%
Citadel Advisors LLC
1.01%
Other
92.27%
Shareholders
Shareholders
Proportion
Lichti (Braeden William Sinclair)
2.37%
Intracoastal Capital, L.L.C.
1.72%
Armistice Capital LLC
1.57%
Northstrive Fund II LP
1.06%
Citadel Advisors LLC
1.01%
Other
92.27%
Shareholder Types
Shareholders
Proportion
Hedge Fund
3.81%
Corporation
2.80%
Individual Investor
2.38%
Investment Advisor/Hedge Fund
0.25%
Investment Advisor
0.02%
Other
90.74%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
20
42.23K
4.08%
+12.91K
2025Q4
21
107.69K
6.48%
--
2025Q3
22
107.69K
7.87%
-5.14K
2025Q2
22
108.63K
1.16%
+96.42K
2025Q1
23
12.21K
4.22%
-11.19K
2024Q4
24
12.14K
4.03%
-17.82K
2024Q3
26
29.96K
1.04%
+23.88K
2024Q2
26
6.08K
2.15%
+5.00K
2024Q1
24
1.08K
7.93%
+549.00
2023Q4
24
499.00
2.34%
+441.00
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Lichti (Braeden William Sinclair)
24.50K
2.37%
--
--
Mar 11, 2026
Intracoastal Capital, L.L.C.
17.81K
1.72%
-25.94K
-59.29%
Dec 31, 2025
Armistice Capital LLC
16.25K
1.57%
+14.51K
+834.98%
Dec 31, 2025
Northstrive Fund II LP
11.00K
1.06%
--
--
Mar 11, 2026
Citadel Advisors LLC
10.45K
1.01%
+10.45K
--
Dec 31, 2025
Renaissance Technologies LLC
8.03K
0.78%
+8.03K
--
Dec 31, 2025
Two Sigma Investments, LP
3.59K
0.35%
+3.59K
--
Dec 31, 2025
Geode Capital Management, L.L.C.
2.56K
0.25%
+1.51K
+144.42%
Dec 31, 2025
Tower Research Capital LLC
1.11K
0.11%
-4.00
-0.36%
Dec 31, 2025
Lana Management & Business Research International LLC
128.00
0.01%
--
--
May 02, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Jan 27, 2026
Merger
4→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Date
Ex-dividend Date
Type
Ratio
Jan 27, 2026
Merger
4→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jul 21, 2023
Merger
20→1
View more
KeyAI